Core Viewpoint - The company forecasts a revenue growth of over 45% year-on-year for 2025, with adjusted net profit (excluding interest income and expenses) also expected to grow over 45% [1][2]. Group 1: Business Performance - The company's core business continues to grow rapidly, solidifying its position as an industry leader, with a projected global market share increase to 24% by 2025 [1]. - The company plans to sign 70 new iCMC projects in 2025, including 22 "winning molecule" projects, with over half being cutting-edge new molecule types or new indications [1]. - The establishment of 10 new PPQ projects, reaching a total of 18 by the end of 2025, lays a solid foundation for revenue growth in the commercialization phase [1]. Group 2: Profitability and Strategic Moves - The company expects a revenue growth rate exceeding 45% in 2025, with gross profit growth surpassing 70%, and adjusted net profit growth (excluding interest income and expenses) also exceeding 45%, with over 65% growth when excluding currency fluctuations [2]. - The company announced a strategic acquisition of Dongyao Pharmaceutical at a maximum total price of approximately HKD 2.79 billion, enhancing its capabilities in the ADC field and shortening capacity expansion cycles [2]. - The company plans to invest over RMB 7 billion from 2026 to 2029 for expansion of conjugation, formulation, and payload connection facilities, with an expansion rate exceeding the industry average [2]. Group 3: Earnings Forecast and Valuation - The company maintains its earnings forecasts for 2025 and 2026, while introducing a net profit forecast of RMB 3.1 billion for 2027 [2]. - The current stock price corresponds to an adjusted P/E of 36.9x for 2026 and 26.9x for 2027, with a target price raised by 17.3% to HKD 88, reflecting an upward potential of 16.2% [2].
药明合联(02268.HK)：25年业绩强劲增长 全球扩张巩固市场领导力